drugset / Trial / NCT00992472

Bioavailability of Prochlorperazine Suppositories, 25 mg

NCT00992472

Phase 1 Completed 42 enrolled Padagis LLC
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to compare prochlorperazine plasma concentrations produced after administration of the test formulation with those produced after administration of a marketed reference product.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Prochlorperazine Small molecule 25 mg Rectal

Indications

No indication recorded.